Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
|Articles|September 21, 2021
Pharmacy Clinical Pearl of the Day: Celiac Disease
Author(s)Saro Arakelians, PharmD
For patients with celiac disease, eating gluten triggers an immune response in the small intestine.
Advertisement
Clinical Pearl of the Day: Celiac Disease
Celiac disease is an immune reaction to eating gluten, a protein found in wheat, barley, and rye.
Explanations:
- In patients with celiac disease, eating gluten triggers an immune response in the small intestine.
- Over time, this reaction damages the small intestine's lining and prevents it from absorbing some nutrients.
- Symptoms include diarrhea, fatigue, weight loss, bloating and gas, abdominal pain, nausea and vomiting, and constipation.
- Risk factors include family members with celiac disease, type 1 diabetes, Down syndrome, autoimmune thyroid disease, microscopic colitis, and Addison disease.
- Diagnosis includes serology testing and genetic testing.
- Treatment includes a gluten-free diet and staying away from foods such as wheat, barley, malt, rye, semolina, and spelt.
- Some patients may be prescribed anti-inflammatory drugs for possible inflammation.
Sources:
Advertisement
Related to this article
About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
The Most Accessible Healthcare Professional—But Accessible to Whom?
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Garlic: Untangling the Complexities of a “Natural” Remedy
5